Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

Samir H Barghout, BSPharm, MSc, Neil MacLean, G. Wei Xu, Geethu Thomas, PhDMSc,BSc, Zachary Blatman, Rose Hurren, BSc, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2018-99-110406

Published: 2018

Journal Articles

Elevated FANCA Expression Marks a Worse Prognosis in Chronic Lymphocytic Leukemia. Evidence of a New Role of FANCA in the Stability of p53 By a Neddylation-Related Mechanism

Carlos Pipaon, PhD, Sara Bravo Navas, Iñigo Romon, MD PhD, Eulogio Conde, MD PhD, Lucrecia Yanez San Segundo, MD PhD

Blood (2018) 132 (Supplement 1): 5541.

https://doi.org/10.1182/blood-2018-99-113398

Published: 2018

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

Journal Articles

Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

Scott R Best, BS, Adam Kittai, MD, Taylor Rowland, BS, Nur Bruss, BS, Stephen E Spurgeon, MD, Allison Berger, PhD, Amy Moran, PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2018-99-115086

Published: 2018

Journal Articles

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Ronan T. Swords, Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, Jesus G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona

Blood (2018) 131 (13): 1415–1424.

https://doi.org/10.1182/blood-2017-09-805895

Published: 2018

Includes: Supplemental data

Journal Articles

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Esther Imperlini, PhD, Massimiliano Gnecchi, MD PhD, Paola Rognoni, PhD, Eduard Sabidò, PhD, Maria Chiara Ciuffreda, Giovanni Palladini, MDPhD, Guadalupe Espadas, Giuseppina Palladini, Stefania Orrù, PhD, Paolo Milani, MD PhD, Stefano Perlini, MD PhD, Francesco Salvatore, MD PhD, Giampaolo Merlini, MD, Francesca Lavatelli, MD PhD

Blood (2017) 130 (Supplement 1): 4393.

https://doi.org/10.1182/blood.V130.Suppl_1.4393.4393

Published: 2017

Journal Articles

TAS4464, a Novel, Highly Potent NEDD8-Activating Enzyme Inhibitor Shows Antitumor Activity in Ibrutinib-Insensitive Mantle Cell Lymphoma Via Inactivation of the NF-κB Pathway

Hiromi Muraoka, MS, Chihoko Yoshimura, PhD, Shingo Tsuji, MS, Akihiro Hashimoto, Fumio Nakagawa, Takashi Mizutani, PhD, Shuichi Ohkubo, PhD, Kenichi Matsuo, PhD, Teruhiro Utsugi, PhD, Yoshikazu Iwasawa, PhD

Blood (2017) 130 (Supplement 1): 4103.

https://doi.org/10.1182/blood.V130.Suppl_1.4103.4103

Published: 2017

Journal Articles

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Samir H. Barghout, BSPharm, MSc, Parasvi Patel, BSc (Hons), Xiaoming Wang, G. Wei Xu, Simon Kavanagh, Marcela Gronda, MSc, Rose Hurren, BSc, Danny V. Jeyaraju, PhD, Neil MacLean, Marc Hyer, PhD, Allison Berger, PhD, Tary Traore, Michael Sintchak, Michael Milhollen, Mark D. Minden, MD PhD, Razq Hakem, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 814.

https://doi.org/10.1182/blood.V130.Suppl_1.814.814

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells

Naxin Guo, PhD, Mary Nemer, Subanky Sivagnanalingam, Mitra Azadniv, PhD, Jason H. Mendler, MD PhD, Michael W. Becker, MD, Jane L. Liesveld, MD

Blood (2017) 130 (Supplement 1): 3820.

https://doi.org/10.1182/blood.V130.Suppl_1.3820.3820

Published: 2017

Journal Articles

TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Scott R Best, Cody Paiva, Taylor Rowland, Bhargava Sreekantham, Stephen E Spurgeon, MD, Allison Berger, PhD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 1533.

https://doi.org/10.1182/blood.V130.Suppl_1.1533.1533

Published: 2017

Journal Articles

Drug Sensitivity Across Acute Myeloid Leukemia Subtypes Using an in Vitro Assay

Levanto Schachter, DO, MSc, Irene M. Hutchins, MD, Jill Waalen, MD MPH, Carol Burian, CCRP, Darren Finlay, PhD, Kristiina Vuori, MD PhD, Giovanni Paternostro, MD PhD, Marin F. Xavier, MD, Carrie L. Costantini, MD, William E. Miller, MD, Jeffrey Andrey, MD, James Mason, MD

Blood (2016) 128 (22): 5208.

https://doi.org/10.1182/blood.V128.22.5208.5208

Published: 2016

Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 98.

https://doi.org/10.1182/blood.V128.22.98.98

Published: 2016

Journal Articles

NEDD8 and HDACs: promising cotargets in AML

Kapil N. Bhalla, Warren Fiskus

Blood (2016) 127 (18): 2168–2170.

https://doi.org/10.1182/blood-2016-02-699058

Published: 2016

Journal Articles

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Natalie M. Czuczman, Matthew J. Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E. Frys, Qiang Hu, Song Liu, Pavel Klener, Petra Vockova, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri

Blood (2016) 127 (9): 1128–1137.

https://doi.org/10.1182/blood-2015-04-640920

Published: 2016

Includes: Supplemental data

NARROW

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

Elevated FANCA Expression Marks a Worse Prognosis in Chronic Lymphocytic Leukemia. Evidence of a New Role of FANCA in the Stability of p53 By a Neddylation-Related Mechanism

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

TAS4464, a Novel, Highly Potent NEDD8-Activating Enzyme Inhibitor Shows Antitumor Activity in Ibrutinib-Insensitive Mantle Cell Lymphoma Via Inactivation of the NF-κB Pathway

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells

TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Drug Sensitivity Across Acute Myeloid Leukemia Subtypes Using an in Vitro Assay

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

NEDD8 and HDACs: promising cotargets in AML

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only